Pfluger Backs Plan to Cut Prescription Drug Costs

WASHINGTON, DC — Congressman August Pfluger (TX-11) released the following statement in response to the Trump administration's biosimilar announcement.

“(The) announcement to make biosimilar development faster and less costly is a major victory in the fight to lower prescription drug prices and expand access for all Americans," he stated. "As Secretary Kennedy noted, 'Parents are facing heartbreaking choices between paying for medication or putting food on their tables. This is not acceptable in the United States of America.' I am proud to stand with the administration on this effort. Senator Lee and I have introduced bipartisan legislation that directly aligns with today's announcement by automatically deeming all biosimilars as interchangeable upon FDA approval and eliminating the unnecessary switching studies that delay patient access. The administration has called on Congress to act, and I'm ready to deliver. Let's get this done and ensure more Americans can access life-saving medications without facing financial burdens.” 

Background:

Earlier this year, Representatives August Pfluger (TX-11) and Greg Landsman (OH-01) introduced legislation to lower prescription drug prices and ensure everyone has affordable access to the medication they need. 

The bipartisan, bicameral Biosimilar Red Tape Elimination Act would improve patient access to lower-cost prescription medications and increase competition in the biological drug market by automatically deeming “biosimilar” drugs as interchangeable with their name-brand counterparts upon FDA approval. This is directly in line with today's announcement. 

Read more on the legislation HERE.